DOD Chronic Pain Management, Investigator-Initiated Research Award | W81XWH 22 CPMRP IIRA

Opportunity Information: Apply for W81XWH 22 CPMRP IIRA

The Department of Defense Chronic Pain Management Research Program (CPMRP) Investigator-Initiated Research Award (IIRA), Funding Opportunity Number W81XWH 22 CPMRP IIRA, is a discretionary research funding opportunity administered by the Department of Defense, Department of the Army, through the U.S. Army Medical Research Acquisition Activity (USAMRAA). It is designed to support investigator-driven projects that can make meaningful, measurable advances in chronic pain research and, importantly, translate into improvements in patient care and/or quality of life within the program's designated FY22 IIRA Focus Areas. The solicitation emphasizes work that has clear potential for significant impact rather than incremental progress, and it encourages applicants to frame their projects around how results could change understanding, management, or outcomes for people living with chronic pain, including Service members and other affected populations.

The award mechanism can be issued as either a grant or a cooperative agreement, and it falls under the Science and Technology and other Research and Development activity category (CFDA 12.420). Eligible applicants are listed as unrestricted, meaning the competition is broadly open to a wide range of organizations and entities, subject to any additional eligibility clarifications contained in the full announcement. The program anticipates making around five awards. While an award ceiling is listed as 0 in the source data, that typically signals that applicants must rely on the full funding announcement for the actual budget limits, cost constraints, and allowable periods of performance rather than interpreting the listing as indicating unlimited or no funding cap.

In terms of scientific scope, the IIRA is intentionally flexible about research stage and approach. Proposed studies may be basic, translational, or clinically oriented and can include work in animal models, studies using human anatomical substances, and research involving human subjects. The opportunity also allows correlative studies tied to an already existing clinical trial, which can be a useful path for teams seeking to leverage data or biospecimens from a trial that is being conducted under separate support. At the same time, the award explicitly cannot be used to conduct clinical trials, so applicants need to ensure their design stays on the right side of that boundary, for example by focusing on observational human-subject research, mechanistic studies, validation of biomarkers, secondary analyses, or ancillary/correlative endpoints connected to a trial that is funded and run through other means.

The program strongly encourages multidisciplinary collaborations and innovative approaches, signaling that proposals that bring together expertise across domains (such as pain medicine, neuroscience, rehabilitation, behavioral health, bioengineering, data science, and implementation science) are especially welcome when the collaboration is integral to the research question and likely to accelerate impact. This emphasis suggests reviewers will value not only scientific rigor but also thoughtful team composition and a plan for integrating methods and perspectives to address chronic pain in a more comprehensive way.

A major policy and mission constraint relates to opioids. Projects that aim to advance new or novel opioid-based therapeutic interventions are considered outside the intent of this mechanism and will not be selected for funding. However, studies that seek to understand and reduce opioid utilization in chronic pain management, within the context of current prescribing practices, are acceptable. In practice, that means the program is open to research that improves opioid stewardship, identifies alternatives or complementary strategies that lower reliance on opioids, evaluates patterns of prescribing and use, or develops tools and interventions that support safer and more effective pain management without developing new opioid drugs.

Key administrative details from the announcement include a creation date of May 24, 2022, and an original closing date of October 13, 2022. Overall, the opportunity is best understood as a competitively awarded DoD research program supporting non-trial chronic pain studies that are investigator-initiated, impactful, and aligned with the FY22 focus areas, while discouraging innovation aimed at new opioid therapeutics and prioritizing approaches that can improve outcomes and quality of life for individuals living with chronic pain.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DOD Chronic Pain Management, Investigator-Initiated Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on May 24, 2022.
• Applicants must submit their applications by Oct 13, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 5 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 CPMRP IIRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: